Indivior (NASDAQ:INDV) Director Barbara Ryan Purchases 775 Shares of Stock

Indivior PLC (NASDAQ:INDV) Director Barbara Ryan acquired 775 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director owned 1,963 shares in the company, valued at approximately $69,470.57. This trade represents a 65.24% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Indivior Stock Performance

INDV opened at $35.89 on Thursday. Indivior PLC has a 1 year low of $7.62 and a 1 year high of $38.00. The company’s 50 day simple moving average is $33.91 and its 200 day simple moving average is $25.66. The stock has a market capitalization of $4.49 billion, a PE ratio of 39.01 and a beta of 0.75.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. The company had revenue of $314.00 million for the quarter, compared to the consensus estimate of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. As a group, sell-side analysts expect that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

INDV has been the subject of a number of research reports. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 price objective (up from $27.00) on shares of Indivior in a research note on Friday, October 31st. Northland Securities set a $40.00 target price on shares of Indivior in a research report on Friday, October 31st. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a report on Friday, October 31st. Finally, HC Wainwright lifted their price target on shares of Indivior from $28.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Indivior presently has an average rating of “Buy” and a consensus target price of $32.71.

Institutional Investors Weigh In On Indivior

Several hedge funds have recently modified their holdings of the stock. CWM LLC acquired a new position in Indivior during the 3rd quarter worth approximately $25,000. Quarry LP purchased a new stake in shares of Indivior during the third quarter valued at approximately $26,000. Raymond James Financial Inc. purchased a new stake in shares of Indivior during the second quarter valued at approximately $26,000. GAMMA Investing LLC lifted its position in shares of Indivior by 544.6% during the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares in the last quarter. Finally, Plato Investment Management Ltd purchased a new position in shares of Indivior in the third quarter valued at $52,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior News Roundup

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: Indivior issued full‑year 2026 guidance calling for total net revenue of $1,125M–$1,195M, SUBLOCADE net revenue of $905M–$945M, non‑GAAP operating expenses of $430M–$450M, and adjusted EBITDA of $535M–$575M. The guidance implies SUBLOCADE will remain the company’s primary revenue driver and an implied adjusted EBITDA margin in the mid‑40% range, which investors view as strong profitability guidance for 2026. Indivior Provides Full-Year 2026 Financial Guidance and Business Update
• Positive Sentiment: Director David E. Wheadon purchased 1,771 shares at an average price of $35.39, increasing his stake by ~14% — a sign of insider confidence. Form 4 — David E. Wheadon
• Positive Sentiment: Directors Mark Stejbach, Daniel A. Ninivaggi, Keith Humphreys and Barbara Ryan each bought 775 shares at ~$35.39, modestly increasing their holdings; combined insider purchases across these filings total roughly 4,871 shares, signaling broad board-level conviction. Form 4 — Mark Stejbach Form 4 — Daniel A. Ninivaggi Form 4 — Keith Humphreys Form 4 — Barbara Ryan

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.